Insider · CIK 0001733883

JOHNSON DAVID LEE

Reports to the SEC for 3 companies · BRISBANE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001733883

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-23	VERAVera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,579 sh	$41.98	−$108K	45,727
2026-02-20	CRBUCaribou Biosciences, Inc. · Option to purchase Common StockA Award	Director	AAward	+45K sh	—	—	45,000
2026-02-04	VERAVera Therapeutics, Inc.A Award	Chief Operating Officer	AAward	+20K sh	—	—	48,306
2026-02-04	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Operating Officer	AAward	+40K sh	—	—	40,000
2025-02-20	CRBUCaribou Biosciences, Inc. · Option to purchase Common StockA Award	Director	AAward	+40.5K sh	—	—	40,500
2025-02-18	VERAVera Therapeutics, Inc.A Award	Chief Operating Officer	AAward	+26.9K sh	—	—	26,900
2025-02-18	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Operating Officer	AAward	+53.8K sh	—	—	53,800
2024-07-01	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Operating Officer	AAward	+160K sh	—	—	160,000
2024-02-20	CRBUCaribou Biosciences, Inc. · Option to purchase Common StockA Award	Director	AAward	+39.5K sh	—	—	39,500
2023-02-21	CRBUCaribou Biosciences, Inc. · Option to purchase Common StockA Award	Director	AAward	+21.5K sh	—	—	21,500
2022-10-05	Global Blood Therapeutics, Inc.D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−34.4K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−3,125 sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−10.9K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−13.8K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−15.5K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−26.5K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−42.4K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−55K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−40K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−38.5K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−38.7K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−28.6K sh	—	—	0
2022-09-28	Global Blood Therapeutics, Inc.G Gift	Chief Commercial Officer	GGift	−22K sh	—	—	34,384
2022-09-01	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,763 sh	—	—	56,279
2022-09-01	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,208 sh	—	—	58,487
2022-09-01	Global Blood Therapeutics, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−2,103 sh	$68.15	−$143K	56,384
2022-09-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,763 sh	—	—	13,814
2022-09-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,208 sh	—	—	15,460
2022-08-31	Global Blood Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+365 sh	$25.37	+$9,260.05	53,516
2022-08-01	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+6,770 sh	—	—	55,493
2022-08-01	Global Blood Therapeutics, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−2,342 sh	$32.40	−$75.9K	53,151
2022-08-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−3,125 sh	—	—	3,125
2022-08-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−3,645 sh	—	—	10,935
2022-05-18	CRBUCaribou Biosciences, Inc. · Option to purchase Common StockA Award	Director	AAward	+44K sh	—	—	44,000
2022-04-01	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+4,375 sh	—	—	49,937
2022-04-01	Global Blood Therapeutics, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−1,513 sh	$35.91	−$54.3K	48,424
2022-04-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−4,375 sh	—	—	0
2022-03-01	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,763 sh	—	—	46,518
2022-03-01	Global Blood Therapeutics, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−956 sh	$29.87	−$28.6K	45,562
2022-03-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,763 sh	—	—	16,577
2022-03-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsA Award	Chief Commercial Officer	AAward	+17.7K sh	—	—	17,668
2022-03-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsA Award	Chief Commercial Officer	AAward	+17.7K sh	—	—	17,668
2022-03-01	Global Blood Therapeutics, Inc.Stock Option (Right to buy)A Award	Chief Commercial Officer	AAward	+28.6K sh	—	—	28,628
2022-02-28	Global Blood Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+472 sh	$25.37	+$12K	43,755
2022-02-01	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+6,770 sh	—	—	45,842
2022-02-01	Global Blood Therapeutics, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−2,559 sh	$29.33	−$75.1K	43,283
2022-02-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−3,125 sh	—	—	6,250
2022-02-01	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−3,645 sh	—	—	14,580
2021-10-01	Global Blood Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+4,375 sh	—	—	41,242
2021-10-01	Global Blood Therapeutics, Inc.F Tax Payment	Chief Commercial Officer	FTax Payment	−2,170 sh	$26.25	−$57K	39,072

Recent filings

Accepted (ET)
Feb 254
JOHNSON DAVID LEE0001733883-26-000006
SEC(opens sec.gov)
Feb 204
JOHNSON DAVID LEE0001733883-26-000004
SEC(opens sec.gov)
Feb 64
JOHNSON DAVID LEE0001733883-26-000002
SEC(opens sec.gov)
Feb 214
JOHNSON DAVID LEE0001733883-25-000003
SEC(opens sec.gov)
Feb 204
JOHNSON DAVID LEE0001415889-25-004844
SEC(opens sec.gov)
Jul 34
JOHNSON DAVID LEE0001415889-24-019162
SEC(opens sec.gov)
Feb 224
JOHNSON DAVID LEE0001628280-24-006407
SEC(opens sec.gov)
Feb 234
JOHNSON DAVID LEE0001619856-23-000016
SEC(opens sec.gov)
Oct 64
JOHNSON DAVID LEE0000899243-22-033150
SEC(opens sec.gov)

Companies

Address

C/O VERA THERAPEUTICS, INC. 2000 SIERRA POINT PARKWAY, SUITE 1200

BRISBANE, CA, 94005